Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells

被引：15
作者：
Kimura, Noriko
Miyakawa, Yoshitaka [1 ]
Kohmura, Kanoko
Umezawa, Kazuo
Ikeda, Yasuo
Kizaki, Masahiro
机构：
[1] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo 1608582, Japan
[2] Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kanagawa, Japan
来源：
LEUKEMIA RESEARCH | 2007年 / 31卷 / 11期
关键词：
NF-kappa B; Burkitt lymphoma; apoptosis; caspase-3; IAP;
D O I：
10.1016/j.leukres.2007.02.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A new NF-kappa B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and INK was induced by DHMEQ. In conclusion, these results demonstrate that NF-kappa B might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1529 / 1535
页数：7
相关论文
共 37 条
  • [31] Activation of NF-κB by HTLV-I and implications for cell transformation
    Sun, SC
    Yamaoka, S
    [J]. ONCOGENE, 2005, 24 (39) : 5952 - 5964
  • [32] Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IkBα-independent manner
    Tatetsu, H
    Okuno, Y
    Nakamura, M
    Matsuno, F
    Sonoki, T
    Taniguchi, I
    Uneda, S
    Umezawa, K
    Mitsuya, H
    Hata, H
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (07) : 1114 - 1120
  • [33] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Thomas, DA
    Faderl, S
    O'Brien, S
    Bueso-Ramos, C
    Cortes, J
    Garcia-Manero, G
    Giles, FJ
    Verstovsek, S
    Wierda, WG
    Pierce, SA
    Shan, JQ
    Brandt, M
    Hagemeister, FB
    Keating, MJ
    Cabanillas, F
    Kantarjian, H
    [J]. CANCER, 2006, 106 (07) : 1569 - 1580
  • [34] Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
    Thomas, DA
    Cortes, J
    O'Brien, S
    Pierce, S
    Faderl, S
    Albitar, M
    Hagemeister, FB
    Cabanillas, FF
    Murphy, S
    Keating, MJ
    Kantarjian, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2461 - 2470
  • [35] Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: Implications for the treatment of Burkitt's lymphoma
    Williams, SA
    Gillan, ER
    Knoppel, E
    Buzby, JS
    Suen, Y
    Cairo, MS
    [J]. ANNALS OF ONCOLOGY, 1997, 8 : 25 - 30
  • [36] Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function
    Wright, CW
    Duckett, CS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) : 2673 - 2678
  • [37] Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors
    Zheng, B
    Georgakis, GV
    Li, Y
    Bharti, A
    McConkey, D
    Aggarwal, BB
    Younes, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (09) : 3207 - 3215
1234